Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H15NO |
| Molecular Weight | 165.2322 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N(C)C)C1=CC(O)=CC=C1
InChI
InChIKey=GQZXRLWUYONVCP-QMMMGPOBSA-N
InChI=1S/C10H15NO/c1-8(11(2)3)9-5-4-6-10(12)7-9/h4-8,12H,1-3H3/t8-/m0/s1
| Molecular Formula | C10H15NO |
| Molecular Weight | 165.2322 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. | 2002 Mar 19 |
|
| A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. | 2004 Apr |
|
| A stability indicating LC method for rivastigmine hydrogen tartrate. | 2005 Feb 7 |
|
| A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. | 2006 |
|
| [Synthesis of S-(+)-rivastigmine hydrogentartrate]. | 2007 Feb |
|
| Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. | 2008 |
|
| Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. | 2008 Feb |
|
| Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. | 2008 Jan |
|
| Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease. | 2009 Feb |
|
| Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product. | 2010 May |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:22:13 UTC 2023
by
admin
on
Sat Dec 16 08:22:13 UTC 2023
|
| Record UNII |
1608PLR9ZO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60161005
Created by
admin on Sat Dec 16 08:22:13 UTC 2023 , Edited by admin on Sat Dec 16 08:22:13 UTC 2023
|
PRIMARY | |||
|
1604811
Created by
admin on Sat Dec 16 08:22:13 UTC 2023 , Edited by admin on Sat Dec 16 08:22:13 UTC 2023
|
PRIMARY | |||
|
139306-10-8
Created by
admin on Sat Dec 16 08:22:13 UTC 2023 , Edited by admin on Sat Dec 16 08:22:13 UTC 2023
|
PRIMARY | |||
|
1608PLR9ZO
Created by
admin on Sat Dec 16 08:22:13 UTC 2023 , Edited by admin on Sat Dec 16 08:22:13 UTC 2023
|
PRIMARY | |||
|
DB04556
Created by
admin on Sat Dec 16 08:22:13 UTC 2023 , Edited by admin on Sat Dec 16 08:22:13 UTC 2023
|
PRIMARY | |||
|
445892
Created by
admin on Sat Dec 16 08:22:13 UTC 2023 , Edited by admin on Sat Dec 16 08:22:13 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
PLASMA
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
